Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer

Science Translational Medicine

Volumn 2, Issue 62, 2010, Pages

  Weiss, Jonathan ^a   Sos, Martin L ^a   Seidel, Danila ^a   Peifer, Martin ^a   Zander, Thomas ^a   Heuckmann, Johannes M ^a   Ullrich, Roland T ^a   Menon, Roopika ^b   Maier, Sebastian ^b   Soltermann, Alex ^c   Moch, Holger ^c   Wagener, Patrick ^d   Fischer, Florian ^a   Heynck, Stefanie ^a   Koker, Mirjam ^a   Schöttle, Jakob ^a   Leenders, Frauke ^a   Gabler, Franziska ^a   Dabow, Ines ^a   Querings, Silvia ^a   Heukamp, Lukas C ^e   Balke Want, Hyatt ^a   Ansén, Sascha ^a   Rauh, Daniel ^f   Baessmann, Ingelore ^g   Altmüller, Janine ^g   Wainer, Zoe ^h   Conron, Matthew ^h   Wright, Gavin ^h   Russell, Prudence ⁱ   Solomon, Ben ^h   Brambilla, Elisabeth ^j,k   Brambilla, Christian ^j,k   Lorimier, Philippe ^j   Sollberg, Steinar ^l   Brustugun, Odd Terje ^l   Engel Riedel, Walburga ^m   Ludwig, Corinna ^m   Petersen, Iver ⁿ   Sänger, Jörg ^o   Clement, Joachim ^p   Groen, Harry ^q   Timens, Wim ^q   Sietsma, Hannie ^q   Thunnissen, Erik ^r   Smit, Egbert ^r   Heideman, Daniëlle ^r   Cappuzzo, Federico ^s   Ligorio, Claudia ^t   Damiani, Stefania ^t   Hallek, Michael ^a   Beroukhim, Rameen ^u,v,w,x   Pao, William ^y   Klebl, Bert ^z   Baumann, Matthias ^z   Buettner, Reinhard ^e   Ernestus, Karen ^m   Stoelben, Erich ^m   Wolf, Jürgen ^a   Nürnberg, Peter ^a,f   Perner, Sven ^b   Thomas, R K ^a,e   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF BONN   (Germany)

^f CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j UNIV GRENOBLE ALPES   (France)

^k INSTITUT ALBERT BONNIOT   (France)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m KLINIKEN DER STADT KÖLN GGMBH   (Germany)

ⁿ JENA UNIVERSITY HOSPITAL   (Germany)

^o Institute for Pathology Bad Berka   (Germany)

^p FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^q UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^r VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^s Ospedale Civile   (Italy)

^t UNIVERSITY OF BOLOGNA   (Italy)

^u DANA FARBER CANCER INSTITUTE   (United States)

^v BRIGHAM AND WOMEN S HOSPITAL   (United States)

^w HARVARD MEDICAL SCHOOL   (United States)

^x BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^y VANDERBILT INGRAM CANCER CENTER   (United States)

^z Lead Discovery Center GmbH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; ENZYME INHIBITOR; PYRIMIDINE DERIVATIVE;

ALLELE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ADENOCARCINOMA; ANIMAL; CELL LINE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MOUSE; NUDE MOUSE; PHYSIOLOGY; RNA INTERFERENCE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650451788     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001451     Document Type: Article

References (36)

1. D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, L. Norton, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
2. M. C. Heinrich, C. L. Corless, G. D. Demetri, C. D. Blanke, M. von Mehren, H. Joensuu, L. S. McGreevey, C. J. Chen, A. D. Van den Abbeele, B. J. Druker, B. Kiese, B. Eisenberg, P. J. Roberts, S. Singer, C. D. Fletcher, S. Silberman, S. Dimitrijevic, J. A. Fletcher, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003).
3. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306-13311 (2004).
4. J. G. Paez, P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, M. Meyerson, EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
5. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
6. T. S. Mok, Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J. J. Yang, B. Chewaskulyong, H. Jiang, E. L. Duffield, C. L. Watkins, A. A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
7. M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
8. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa,M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
9. S. A. Khuder, Effect of cigarette smoking on major histological types of lung cancer: A meta-analysis. Lung Cancer 31, 139-148 (2001).
10. A. J. Bass, H. Watanabe, C. H. Mermel, S. Yu, S. Perner, R. G. Verhaak, S. Y. Kim, L. Wardwell, P. Tamayo, I. Gat-Viks, A. H. Ramos, M. S. Woo, B. A. Weir, G. Getz, R. Beroukhim, M. O'Kelly, A. Dutt, O. Rozenblatt-Rosen, P. Dziunycz, J. Komisarof, L. R. Chirieac, C. J. Lafargue, V. Scheble, T. Wilbertz, C. Ma, S. Rao, H. Nakagawa, D. B. Stairs, L. Lin, T. J. Giordano, P. Wagner, J. D. Minna, A. F. Gazdar, C. Q. Zhu, M. S. Brose, I. Cecconello, U. Ribeiro Jr., S. K. Marie, O. Dahl, R. A. Shivdasani, M. S. Tsao, M. A. Rubin, K. K. Wong, A. Regev, W. C. Hahn, D. G. Beer, A. K. Rustgi, M. Meyerson, SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238-1242 (2009).
11. R. Pirker, J. R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, K. Park, C. T. Yu, V. Ganul, J. K. Roh, E. Bajetta, K. O'Byrne, F. de Marinis, W. Eberhardt, T. Goddemeier, M. Emig, U. Gatzemeier; FLEX Study Team, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373, 1525-1531 (2009).
12. A. Sandler, R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, R. Lilenbaum, D. H. Johnson, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
13. R. Beroukhim, G. Getz, L. Nghiemphu, J. Barretina, T. Hsueh, D. Linhart, I. Vivanco, J. C. Lee, J. H. Huang, S. Alexander, J. Du, T. Kau, R. K. Thomas, K. Shah, H. Soto, S. Perner, J. Prensner, R. M. Debiasi, F. Demichelis, C. Hatton, M. A. Rubin, L. A. Garraway, S. F. Nelson, L. Liau, P. S. Mischel, T. F. Cloughesy, M. Meyerson, T. A. Golub, E. S. Lander, I. K. Mellinghoff, W. R. Sellers, Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc. Natl. Acad. Sci. U.S.A. 104, 20007-20012 (2007).
14. R. Beroukhim, C. H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Barretina, J. S. Boehm, J. Dobson, M. Urashima, K. T. Mc Henry, R. M. Pinchback, A. H. Ligon, Y. J. Cho, L. Haery, H. Greulich, M. Reich, W. Winckler, M. S. Lawrence, B. A. Weir, K. E. Tanaka, D. Y. Chiang, A. J. Bass, A. Loo, C. Hoffman, J. Prensner, T. Liefeld, Q. Gao, D. Yecies, S. Signoretti, E. Maher, F. J. Kaye, H. Sasaki, J. E. Tepper, J. A. Fletcher, J. Tabernero, J. Baselga, M. S. Tsao, F. Demichelis, M. A. Rubin, P. A. Janne, M. J. Daly, C. Nucera, R. L. Levine, B. L. Ebert, S. Gabriel, A. K. Rustgi, C. R. Antonescu, M. Ladanyi, A. Letai, L. A. Garraway, M. Loda, D. G. Beer, L. D. True, A. Okamoto, S. L. Pomeroy, S. Singer, T. R. Golub, E. S. Lander, G. Getz, W. R. Sellers, M. Meyerson, The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
15. B. A. Weir, M. S. Woo, G. Getz, S. Perner, L. Ding, R. Beroukhim, W. M. Lin, M. A. Province, A. Kraja, L. A. Johnson, K. Shah, M. Sato, R. K. Thomas, J. A. Barletta, I. B. Borecki, S. Broderick, A. C. Chang, D. Y. Chiang, L. R. Chirieac, J. Cho, Y. Fujii, A. F. Gazdar, T. Giordano, H. Greulich, M. Hanna, B. E. Johnson, M. G. Kris, A. Lash, L. Lin, N. Lindeman, E. R. Mardis, J. D. McPherson, J. D. Minna, M. B. Morgan, M. Nadel, M. B. Orringer, J. R. Osborne, B. Ozenberger, A. H. Ramos, J. Robinson, J. A. Roth, V. Rusch, H. Sasaki, F. Shepherd, C. Sougnez, M. R. Spitz, M. S. Tsao, D. Twomey, R. G. Verhaak, G. M. Weinstock, D. A. Wheeler, W. Winckler, A. Yoshizawa, S. Yu, M. F. Zakowski, Q. Zhang, D. G. Beer, I. I. Wistuba, M. A. Watson, L. A. Garraway, M. Ladanyi, W. D. Travis, W. Pao, M. A. Rubin, S. B. Gabriel, R. A. Gibbs, H. E. Varmus, R. K. Wilson, E. S. Lander, M. Meyerson, Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
16. C. Greenman, P. Stephens, R. Smith, G. L. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. Teague, A. Butler, C. Stevens, S. Edkins, S. O'Meara, I. Vastrik, E. E. Schmidt, T. Avis, S. Barthorpe, G. Bhamra, G. Buck, B. Choudhury, J. Clements, J. Cole, E. Dicks, S. Forbes, K. Gray, K. Halliday, R. Harrison, K. Hills, J. Hinton, A. Jenkinson, D. Jones, A. Menzies, T. Mironenko, J. Perry, K. Raine, D. Richardson, R. Shepherd, A. Small, C. Tofts, J. Varian, T. Webb, S. West, S. Widaa, A. Yates, D. P. Cahill, D. N. Louis, P. Goldstraw, A. G. Nicholson, F. Brasseur, L. Looijenga, B. L. Weber, Y. E. Chiew, A. DeFazio, M. F. Greaves, A. R. Green, P. Campbell, E. Birney, D. F. Easton, G. Chenevix-Trench, M. H. Tan, S. K. Khoo, B. T. Teh, S. T. Yuen, S. Y. Leung, R. Wooster, P. A. Futreal, M. R. Stratton, Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
17. M. L. Sos, K. Michel, T. Zander, J.Weiss, P. Frommolt, M. Peifer, D. Li, R. Ullrich, M. Koker, F. Fischer, T. Shimamura, D. Rauh, C. Mermel, S. Fischer, I. Stückrath, S. Heynck, R. Beroukhim, W. Lin, W. Winckler, K. Shah, T. LaFramboise, W. F. Moriarty, M. Hanna, L. Tolosi, J. Rahnenführer, R. Verhaak, D. Chiang, G. Getz, M. Hellmich, J. Wolf, L. Girard, M. Peyton, B. A. Weir, T. H. Chen, H. Greulich, J. Barretina, G. I. Shapiro, L. A. Garraway, A. F. Gazdar, J. D. Minna, M. Meyerson, K. K. Wong, R. K. Thomas, Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 119, 1727-1740 (2009).
18. U. McDermott, S. V. Sharma, L. Dowell, P. Greninger, C. Montagut, J. Lamb, H. Archibald, R. Raudales, A. Tam, D. Lee, S. M. Rothenberg, J. G. Supko, R. Sordella, L. E. Ulkus, A. J. Iafrate, S. Maheswaran, C. N. Njauw, H. Tsao, L. Drew, J. H. Hanke, X. J. Ma, M. G. Erlander, N. S. Gray, D. A. Haber, J. Settleman, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl. Acad. Sci. U.S.A. 104, 19936-19941 (2007).
19. M. Mohammadi, S. Froum, J. M. Hamby, M. C. Schroeder, R. L. Panek, G. H. Lu, A. V. Eliseenkova, D. Green, J. Schlessinger, S. R. Hubbard, Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904 (1998).
20. M. L. Sos, S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stückrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K. A. Politi, S. Perera, M. Getlik, L. C. Heukamp, S. Ansén, T. Zander, R. Beroukhim, H. Kashkar, K. M. Shokat, W. R. Sellers, D. Rauh, C. Orr, K. P. Hoeflich, L. Friedman, K. K. Wong, W. Pao, R. K. Thomas, Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. U.S.A. 106, 18351-18356 (2009).
21. L. Marek, K. E. Ware, A. Fritzsche, P. Hercule, W. R. Helton, J. E. Smith, L. A. McDermott, C. D. Coldren, R. A. Nemenoff, D. T. Merrick, B. A. Helfrich, P. A. Bunn Jr., L. E. Heasley, Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 75, 196-207 (2009).
22. W. Zhou, W. Hur, U. McDermott, A. Dutt,W. Xian, S. B. Ficarro, J. Zhang, S. V. Sharma, J. Brugge, M. Meyerson, J. Settleman, N. S. Gray, A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol. 17, 285-295 (2010).
23. S. Blencke, B. Zech, O. Engkvist, Z. Greff, L. Orfi, Z. Horváth, G. Kéri, A. Ullrich, H. Daub, Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691-701 (2004).
24. G. Tonon, K. K. Wong, G. Maulik, C. Brennan, B. Feng, Y. Zhang, D. B. Khatry, A. Protopopov, M. J. You, A. J. Aguirre, E. S. Martin, Z. Yang, H. Ji, L. Chin, R. A. Depinho, High-resolution genomic profiles of human lung cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 9625-9630 (2005).
25. K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J. M. Ren, J. Yuan, C. E. Bakalarski, J. Villen, J. M. Kornhauser, B. Smith, D. Li, X. Zhou, S. P. Gygi, T. L. Gu, R. D. Polakiewicz, J. Rush, M. J. Comb, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
26. U. McDermott, R. Y. Ames, A. J. Iafrate, S. Maheswaran, H. Stubbs, P. Greninger, K. McCutcheon, R. Milano, A. Tam, D. Y. Lee, L. Lucien, B. W. Brannigan, L. E. Ulkus, X. J. Ma, M. G. Erlander, D. A. Haber, S. V. Sharma, J. Settleman, Ligand-dependent platelet-derived growth factor receptor (PDGFR)-a activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 69, 3937-3946 (2009).
27. A. H. Ramos, A. Dutt, C. Mermel, S. Perner, J. Cho, C. J. Lafargue, L. A. Johnson, A. C. Stiedl, K. E. Tanaka, A. J. Bass, J. Barretina, B. A. Weir, R. Beroukhim, R. K. Thomas, J. D. Minna, L. R. Chirieac, N. I. Lindeman, T. Giordano, D. G. Beer, P. Wagner, I. I. Wistuba, M. A. Rubin, M. Meyerson, Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol. Ther. 8, 2042-2050 (2009).
28. X. Zhao, B. A. Weir, T. LaFramboise, M. Lin, R. Beroukhim, L. Garraway, J. Beheshti, J. C. Lee, K. Naoki, W. G. Richards, D. Sugarbaker, F. Chen, M. A. Rubin, P. A. Jänne, L. Girard, J. Minna, D. Christiani, C. Li, W. R. Sellers, M. Meyerson, Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65, 5561-5570 (2005).
29. J. S. Reis-Filho, P. T. Simpson, N. C. Turner, M. B. Lambros, C. Jones, A. Mackay, A. Grigoriadis, D. Sarrio, K. Savage, T. Dexter, M. Iravani, K. Fenwick, B. Weber, D. Hardisson, F. C. Schmitt, J. Palacios, S. R. Lakhani, A. Ashworth, FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12, 6652-6662 (2006).
30. N. Turner, R. Grose, Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 10, 116-129 (2010).
31. N. Turner, A. Pearson, R. Sharpe, M. Lambros, F. Geyer, M. A. Lopez-Garcia, R. Natrajan, C. Marchio, E. Iorns, A. Mackay, C. Gillett, A. Grigoriadis, A. Tutt, J. S. Reis-Filho, A. Ashworth, FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085-2094 (2010).
32. http://www.broadinstitute.org/igv/.
33. S. Perner, P. L. Wagner, A. Soltermann, C. LaFargue, V. Tischler, B. A. Weir, W. Weder, M. Meyerson, T. J. Giordano, H. Moch, M. A. Rubin, TTF1 expression in non-small cell lung carcinoma: Association with TTF1 gene amplification and improved survival. J. Pathol. 217, 65-72 (2009).
34. http://www.broadinstitute.org/cancer/software/genepattern/.
35. M. L. Sos, H. B. Rode, S. Heynck, M. Peifer, F. Fischer, S. Klüter, V. G. Pawar, C. Reuter, J. M. Heuckmann, J. Weiss, L. Ruddigkeit, M. Rabiller, M. Koker, J. R. Simard, M. Getlik, Y. Yuza, T. H. Chen, H. Greulich, R. K. Thomas, D. Rauh, Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 70, 868-874 (2010).
36. Acknowledgments: We thank M. Meyerson and A. Bass for sharing unpublished data and C. Reinhardt and A. Ullrich for discussion. Funding: This work was supported by the Deutsche Krebshilfe (grant 107954 to R.K.T.); the GermanMinistry of Science and Education (BMBF) as part of the NGFNplus program (grants 01GS08100 to R.K.T. and 01GS08101 to J. Wolf and P.N.); the Max Planck Society (M.I.F.A.NEUR8061 to R.K.T.); the Deutsche Forschungsgemeinschaft (DFG) through SFB (TP6 to R.K.T. and R.T.U.; TP5 to L.C.H. and R. Buettner); the Ministry for Innovation, Science, Research and Technology of the State of Nordrhein-Westfalen (MIWT, 4000-12 09 to R.K.T. and B.K.); and an anonymous foundation to R.K.T. E.B. and C.B. were supported by the PNES INCA grant 2008. B.S. was supported by the International Association for the Study of Lung Cancer Young Investigator Award.W.P. was supported by a grant fromthe NIH National Cancer Institute. Z.W. was supported by the Royal Australasian College of Surgeons and a Raelene Boyle Scholarship. G.W. was supported by the Australasian Society of Cardiac and Thoracic Surgeons Foundation Grant, Peter MacCallum Foundation Grant, and a private research donation from family and friends of former patients. Author contributions: J. Weiss and M.L.S. designed and performed the experiments, analyzed the data, and wrote the manuscript. D.S. designed the experiments and analyzed the data. M.P., T.Z., F.L., andD.R. analyzed the data. J.M.H., R.T.U., R.M., S.M., F.F., S.H., M.K., J. Schöttle, F.G., I.D., S.Q., L.C.H., H.B.-W., I.B., and J.A. performed the experiments and discussed the data. A.S., H.M., P.W., S.A., Z.W., M.C., G.W., P.R., B.S., E.B., C.B., P.L., S.S., O.T.B.,W.E.-R., C.L., I.P., J. Sänger, J.C., H.G.,W.T., H.S., E.T., E. Smit, D.H., F.C., C.L., S.D., M.H., R. Beroukhim, W.P., B.K., M.B., R. Buettner, K.E., E. Stoelben, J. Wolf, and P.N. contributed critical tumor specimens and contributed to the discussion of the data. S.P. reviewed tumor histology, analyzed the FISH data, and wrote the manuscript. R.K.T. conceived the project, designed the experiments, analyzed the data, and wrote the manuscript. Competing interests: R.K.T. receives consulting and lecture fees fromSequenom, Sanofi-Aventis,Merck, Roche, Infinity, Boehringer, AstraZeneca, and ATLAS Biolabs, as well as research support from Novartis and AstraZeneca. J. Wolf is a member of advisory boards of Roche, AstraZeneca, Novartis, Amgen, Bayer, andMerck and has received lecture fees fromRoche, AstraZeneca, andMerck. R. Beroukhim receives consulting fees for Novartis Institutes for BioMedical Research. W.P. receives consulting fees from Molecular MD, AstraZeneca, BMS, and Symphony Evolution. H.G. received research support from Eli Lilly, Roche, and Boehringer Ingelheim through the University Medical Center Groningen. The other authors declare that they have no competing interests. Accession numbers: All raw data are publicly available (GEO; GSE25016).